Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 776-780

  Lim, Young Chang ^a   Cha, Yun Yi ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

anaplastic carcinoma; apoptosis; EGCG; thyroid gland

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CDK1 PROTEIN; CELL CYCLE PROTEIN; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; JANUS KINASE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CARCINOMA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CARCINOMA; CATECHIN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 80255132722     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21999     Document Type: Article

References (26)

1. Are C, Shaha AR,: Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453-464.
2. McIver B, Hay ID, Giuffrida DF, et al.: Anaplastic thyroid carcinoma: A 50-year experience at a single institution. Surgery 2001; 130: 1028-1034. (Pubitemid 34014569)
3. Normanno N, De Luca A, Bianco C, et al.: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16. (Pubitemid 43199589)
4. Shin DM, Ro JY, Hong WK,: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 3153-3159. (Pubitemid 24208920)
5. Ettinger DS,: Clinical implications of EGFR expression in the development and progression of solid tumors: Focus on non-small cell lung cancer. Oncologist 2006; 11: 358-373.
6. Lurje G, Lenz HJ,: EGFR signaling and drug discovery. Oncology 2009; 77: 400-410.
7. Schiff BA, McMurphy AB, Jasser SA, et al.: Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004; 10: 8594-8602. (Pubitemid 40053427)
8. Duh QY, Gum ET, Gerend PL, et al.: Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985; 98: 1000-1007. (Pubitemid 16104717)
9. Hartmann JT, Haap M, Kopp HG, et al.: Tyrosine kinase inhibitors-A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-481.
10. Surh YJ,: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-780.
11. Khan N, Afaq F, Saleem M, et al.: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500-2506.
12. Shimizu M, Deguchi A, Lim JT, et al.: (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005; 11: 2735-2746. (Pubitemid 40569476)
13. Nobuhara Y, Onoda N, Yamashita Y, et al.: Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005; 92: 1110-1116. (Pubitemid 40546677)
14. Ensinger C, Spizzo G, Moser P, et al.: Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann N Y Acad Sci 2004; 1030: 69-77. (Pubitemid 40378898)
15. Chen BK, Ohtsuki Y, Furihata M, et al.: Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15: 893-898.
16. Kimura ET, Nikiforova MN, Zhu Z, et al.: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-1457. (Pubitemid 36373628)
17. Quiros RM, Ding HG, Gattuso P, et al.: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103: 2261-2268. (Pubitemid 40686569)
18. Santarpia L, El-Naggar AK, Cote GJ, et al.: Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008; 93: 278-284.
19. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
20. Knauf JA, Fagin JA,: Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009; 21: 296-303.
21. Milligan SA, Burke P, Coleman DT, et al.: The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009; 15: 4885-4894.
22. Thangapazham RL, Singh AK, Sharma A, et al.: Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007; 245: 232-241. (Pubitemid 44959362)
23. Larsen CA, Dashwood RH,: (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys 2010; 501: 52-57.
24. Wang X, Hao MW, Dong K, et al.: Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res 2009; 32: 1263-1269.
25. Malumbres M, Barbacid M,: Cell cycle, CDKs, and cancer: A changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
26. Davis CD, Emenaker NJ, Milner JA,: Cellular proliferation, apoptosis and angiogenesis: Molecular targets for nutritional preemption of cancer. Semin Oncol 2010; 37: 243-257.